Skip to main
BIO

Bio-Rad Laboratories (BIO) Stock Forecast & Price Target

Bio-Rad Laboratories (BIO) Analyst Ratings

Based on 3 analyst ratings
Hold
Strong Buy 0%
Buy 33%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Bio-Rad Laboratories is poised for growth in the coming years due to its diverse product portfolio and strong market positioning in its clinical diagnostics and life sciences divisions. The company's exposure to the conflict in the Middle East may have a short-term impact on its sales, but overall, the sales growth is expected to recover in 2027 after lapping headwinds related to process chromatography. Additionally, the recent restructuring efforts and new management team are expected to improve margins and drive further growth. The termination of the Sartorius Trust in 2028 will also increase the optionality and value of Bio-Rad's ownership stake in the company. While there are potential risks, such as a delay in end market recovery and competition in the ddPCR market, the company's strong product portfolio and focus on sustainability make it a compelling investment opportunity.

Bears say

Bio-Rad Laboratories is facing several challenges that are unique to the company, including declines in process chromatography sales due to changes in the CDC's immunization recommendations. However, the company's management is taking proactive steps to improve efficiencies and reduce expenses, which could result in a mid-teens operating margin goal by 2028-2029. There is also potential for upside in the company's ownership stake in Sartorius, which may become more valuable after the controlling Trust terminates in mid-2028. However, there are still risks to consider, such as a prolonged recovery in the life science tools industry and potential share losses in ddPCR. These factors warrant a cautious approach to Bio-Rad's stock, which is why the analyst has a negative outlook and a target price of $390, a discount to the peer group.

Bio-Rad Laboratories (BIO) has been analyzed by 3 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 33% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bio-Rad Laboratories and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bio-Rad Laboratories (BIO) Forecast

Analysts have given Bio-Rad Laboratories (BIO) a Hold based on their latest research and market trends.

According to 3 analysts, Bio-Rad Laboratories (BIO) has a Hold consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $350, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $350, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bio-Rad Laboratories (BIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.